Helen Anaedo, MD
Endocrinology, Diabetes & Metabolism · Plainville, CTNPI 1164717021
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,743 of the $9,403 with a category attached, or 61.1%. 24 manufacturers reported payments, led by Corcept Therapeutics at 39.7% of the total. Reporting peaked in 2019 at $4,755 and has fallen 70.4% since, to $1,407 in 2025.
Across 145 payments — averaging $64.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$4K
- Tandem Diabetes Care, Inc.$1K
- Abbott$1K
- Novo Nordisk$853
- Dexcom, Inc.$577
- Amgen$564
- plus $2K from 18 others
What the payments were for
- Consulting fees$2,25024%
- Travel & lodging$1,33014%
- Food & beverage$5,74361%
- Education$200%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 7 | $3,730 |
| Tandem Diabetes Care, Inc. | 9 | $1,085 |
| Abbott | 18 | $1,002 |
| Novo Nordisk | 32 | $853 |
| Dexcom, Inc. | 20 | $577 |
| Amgen | 12 | $564 |
| Medtronic | 5 | $254 |
| AstraZeneca | 2 | $231 |
| Lilly USA, LLC | 8 | $228 |
| Mannkind Corporation | 4 | $127 |
| Radius Health, Inc. | 2 | $125 |
| Xeris Pharmaceuticals, Inc. | 6 | $108 |
| AbbVie | 1 | $99 |
| Bayer | 5 | $94 |
| Novartis | 3 | $79 |
| Insulet Corporation | 2 | $55 |
| Sequel Med Tech, LLC | 2 | $42 |
| Sanofi-aventis U.S. LLC | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| IBSA Pharma Inc. | 1 | $25 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| BETA Bionics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$3,730
- t-slim insulin pump$851
- FREESTYLE LIBRE 3$775
- EVENITY$368
- FARXIGA$231
- Ozempic$123
- DEXCOM G6 TRANSMITTER$115
- MINIMED 780G$114
- Tymlos$106
- t:slim X2 insulin pump$100
How this compares
$9,403 in reported general payments places this provider in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
See all endocrinology, diabetes & metabolism providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 251 | $413,603 |
| JardianceEmpagliflozin | 187 | $264,650 |
| MounjaroTirzepatide | 137 | $166,026 |
| TrulicityDulaglutide | 78 | $118,563 |
| RybelsusSemaglutide | 47 | $102,379 |
| FarxigaDapagliflozin Propanediol | 66 | $77,829 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $58,400 |
| JanuviaSitagliptin Phosphate | 33 | $42,272 |
| Teriparatide | 19 | $41,431 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $30,508 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 29 | $24,260 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 12 | $22,587 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 127 | $19,029 |
| Novolog FlexpenInsulin Aspart | 57 | $17,695 |
| SynthroidLevothyroxine Sodium | 174 | $17,641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $853 | $522,384312 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $26 | $295,159206 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $228 | $288,582226 claims |
| AstraZenecaFarxiga | $231 | $77,82966 claims |
| AbbVieSynthroid | $99 | $17,641174 claims |
| IBSA Pharma Inc.Tirosint | $25 | $4,19612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 endocrinology, diabetes & metabolism providers in Connecticut.
Other endocrinology, diabetes & metabolism in Plainville
- Egils BogdanovicsTorrington$608K
- Ania JastreboffNew Haven$536K
- Robert ObersteinHartford$516K
- Fadi Al-KhayerStorrs$489K
- Silvio InzucchiNew Haven$461K
- Philip GoldbergNew Haven$324K
- Kevan HeroldNew Haven$261K
- Joseph RosenblattNew Britain$235K
- David DomenichiniBloomfield$220K
- Glenn RichTrumbull$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.